• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ADC Therapeutics SA Common Shares (NY:ADCT)

    3.720 +0.050 (+1.36%)
    Official Closing Price Updated: 7:00 PM EDT, Apr 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about ADC Therapeutics SA Common Shares

    < Previous 1 2 3 4 5 Next >
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough
    EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:TEVA),(NASDAQ:CTOR),(NYSE:ADCT),(NYSE:OSTX) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics to Present at Upcoming Investor Conferences
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
    From ADC Therapeutics SA
    Via GlobeNewswire
    News headline image
    ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
    From ADC Therapeutics SA
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.